Furthermore, the R72 variant was shown to harbour increased AMPK-sensitivity as measured by p53-Ser15 phosphorylation in glucose-deprived cancer cell lines and in liver and pancreas of mice treated with the AMPK activator AICAR39. This evidence concerns the gene TP53 and cancer.